Dr. Ramalingam on Next Steps With Nivolumab/Ipilimumab in NSCLC


Suresh S. Ramalingam, MD, FASCO, discusses the utility of nivolumab plus ipilimumab in metastatic or recurrent non–small cell lung cancer.

Suresh S. Ramalingam, MD, FASCO, deputy director, ​director, Lung Cancer Program, Winship Cancer Institute of Emory University, Roberto C. Goizueta Distinguished Chair for Cancer Research, professor, assistant dean for cancer research, director, Division of Medical Oncology, Department of Hematology and Medical Oncology, Emory University School of Medicine, discusses the utility of nivolumab (Opdivo) plus ipilimumab (Yervoy) in metastatic or recurrent non–small cell lung cancer (NSCLC).

In May 2020, the FDA approved the combination of nivolumab (Opdivo) plus ipilimumab (Yervoy) for the frontline treatment of patients with PD-L1–positive metastatic NSCLC based on findings from the phase 3 CheckMate-227 trial. This provides patients with a chemotherapy-free option that has the ability to prolong survival, says Ramalingam.

The next step is to evaluate the combination in other settings of NSCLC, such as in the stage III setting wherein patients receive concurrent chemoradiation followed by consolidative immunotherapy, explains Ramalingam.

Additionally, this ​regimen may serve as a backbone for other novel agents to build upon, Ramalingam concludes.

Related Videos
Jeremy L. Ramdial, MD, assistant professor, Department of Stem Cell Transplantation and Cellular Therapy, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center
Alexandra Gomez Arteaga, MD, Weill Cornell Medicine/New York-Presbyterian Hospital
Rahul Banerjee, MD, FACP, assistant professor, Clinical Research Division, Fred Hutchinson Cancer Center; assistant professor, Division of Hematology and Oncology, University of Washington
Alice Bertaina, MD, PhD
Jeffery Auletta, MD, The Ohio State University College of Medicine
Betty Hamilton, MD, Cleveland Clinic
Stephanie Lee, MD, MPH, Fred Hutchinson Cancer Center
Chul Kim, MD, MPH
Neil D. Gross, MD, FACS
Dae Won Kim, MD, Gastrointestinal Oncology Program, Moffitt Cancer Center